Import from '@womanrx/components'

Intrarosa (Prasterone Vaginal DHEA) and Your Kidneys: Renal Protection or Renal Risk?

What Is Prasterone (Intrarosa) and Why Does the Kidney Question Come Up?

Prasterone is the pharmaceutical name for dehydroepiandrosterone (DHEA) formulated as a 6.5 mg vaginal insert used nightly. The FDA cleared it in 2016 for moderate-to-severe dyspareunia caused by genitourinary syndrome of menopause (GSM). Because DHEA is a steroid precursor that converts locally to estrogens and androgens, women with kidney disease or their nephrologists sometimes ask two opposite questions: could this drug harm my kidneys, or could it actually protect them?

The question is not unfounded. DHEA receptors and DHEA-metabolizing enzymes are present in renal tubular cells, and animal experiments have shown DHEA can blunt diabetic nephropathy progression. At the same time, sex steroids broadly influence renal hemodynamics, and any new steroid-adjacent compound reasonably raises caution flags for women with existing chronic kidney disease (CKD).

This article works through both sides of that question using the best available evidence, tells you what was and was not measured in the key trials, and explains how life stage affects what you and your clinician should watch for.

How Much Systemic DHEA Actually Reaches Your Bloodstream?

The short answer is: very little, and that is by design.

Pharmacokinetics After Vaginal Administration

Vaginal tissue metabolizes prasterone locally into estradiol and testosterone before much of it reaches the systemic circulation. In the phase III trial that led to FDA approval, women using the 6.5 mg insert nightly showed serum DHEA-S levels that remained within the normal postmenopausal reference range, rising only modestly above baseline. Serum estradiol and testosterone also stayed within postmenopausal norms, well below the concentrations reached with systemic hormone therapy.

This is pharmacologically meaningful for the kidney question. The renal effects attributed to DHEA in animal studies occur at concentrations that systemic DHEA replacement studies achieve, not at the trace systemic exposure from a nightly vaginal insert. Extrapolating dramatic preclinical renal findings to vaginal prasterone requires crossing several assumptions that the existing data do not support.

Why Women's Bodies Handle This Differently Than Men's

Women have lower baseline DHEA-S levels than age-matched men, a gap that widens substantially after menopause. DHEA-S declines roughly 10-20% per decade from its peak in the third decade of life, meaning a postmenopausal woman in her 60s may have DHEA-S levels 70-80% below her own peak. Vaginal prasterone does not restore DHEA-S to premenopausal levels; it produces a small, local effect with a negligible systemic steroid rise. This sex-specific pharmacokinetic context matters when you read preclinical renal-protection literature written almost entirely in male rodent models.

Evidence for Renal Harm: What the Key Trials Actually Measured

The Phase III GSM Trials

The principal efficacy trial published in Menopause (2016) enrolled 418 postmenopausal women with moderate-to-severe dyspareunia and randomized them to prasterone 6.5 mg or placebo nightly for 12 weeks. The co-primary endpoints were changes in vaginal cytology (superficial and parabasal cell percentages), vaginal pH, and patient-reported dyspareunia severity. Prasterone outperformed placebo on all four co-primary endpoints.

Renal function was not a primary or secondary endpoint. Adverse event tables did not flag renal or urinary events as differentially elevated in the prasterone arm. This is reassuring as a safety signal, but it is not a systematic evaluation of renal function. Serum creatinine, estimated glomerular filtration rate (eGFR), or urinary albumin-to-creatinine ratio were not specifically tracked or reported.

What We Can and Cannot Conclude

Women with established CKD, nephrotic syndrome, or prior renal transplant were not specifically studied. Because trial populations typically excluded women with serious comorbidities, the absence of documented renal harm in the trials reflects a healthier-than-average sample, not a clean bill of safety for women with significant baseline renal impairment.

The honest summary: no signal of renal harm was detected in 12-week trials in generally healthy postmenopausal women. Longer-term renal data in women with pre-existing CKD does not exist in the published prasterone literature.

Evidence for Renal Protection: What the Science Actually Shows

This is where the topic gets more nuanced, and where the evidence gap is real.

Preclinical Data

Multiple animal studies have shown that DHEA supplementation can reduce markers of renal injury in rodent models of diabetic nephropathy, reducing proteinuria, glomerular hypertrophy, and fibrosis. One mechanism proposed is DHEA-mediated activation of peroxisome proliferator-activated receptor alpha (PPAR-alpha) in proximal tubular cells, which may reduce lipid accumulation and oxidative stress. Another proposed pathway involves DHEA's conversion to estradiol in renal tissue, since estrogen is generally considered reno-protective compared to testosterone.

These are mechanistically plausible pathways. They are not clinical outcomes data.

Small Human Studies

A 2018 observational analysis in postmenopausal women with type 2 diabetes found that higher endogenous DHEA-S levels were independently associated with slower eGFR decline over a median follow-up of 4 years. The association persisted after adjustment for age, BMI, and HbA1c, with a hazard ratio suggesting roughly a 20% lower risk of CKD progression per standard deviation increase in DHEA-S.

This is observational, subject to confounding, and measured endogenous DHEA-S rather than a vaginal prasterone intervention. Correlation between higher endogenous DHEA-S and better renal outcomes does not mean that adding exogenous vaginal DHEA in a woman with low endogenous DHEA-S will replicate that protection.

A Framework for Interpreting the Renal-Protection Claim

When you see claims that "Intrarosa protects the kidneys," apply this three-question test:

1. Was the study done with vaginal prasterone specifically, or with oral or injectable DHEA at systemic doses? Almost all renal-protection data comes from the latter.
2. Was the study in women, or in male rodents or predominantly male human cohorts? Most preclinical data is male-model derived.
3. Was renal function a pre-specified endpoint with adequate power, or an incidental observation? Even the human observational data was not designed to test vaginal prasterone.

Until a trial specifically enrolls women with CKD or metabolic kidney disease, randomizes them to vaginal prasterone versus placebo, and pre-specifies eGFR or proteinuria as endpoints, "Intrarosa protects the kidneys" remains a hypothesis worth studying, not a clinical recommendation you should rely on.

Prasterone Across Life Stages: Who Gets GSM and Who Asks About Kidneys?

Perimenopause

Perimenopause, typically beginning in the mid-to-late 40s, brings fluctuating estrogen levels but ovulation and menstrual cycles still occur. ACOG acknowledges that GSM symptoms can begin during perimenopause as estrogen starts to decline. Prasterone is FDA-labeled for postmenopausal women and is not indicated during perimenopause. Women in perimenopause who have not yet had 12 consecutive months without menstruation require reliable contraception if using any hormone-adjacent therapy (see Pregnancy section below).

Postmenopause

This is the approved life stage for Intrarosa. GSM affects an estimated 27-84% of postmenopausal women, with wide prevalence ranges depending on how symptoms are assessed and how directly they are asked about. For postmenopausal women who also have CKD, the conversation about Intrarosa's renal profile is particularly relevant.

Women With PCOS in Reproductive Years

Women with polycystic ovary syndrome often have elevated endogenous DHEA-S, and PCOS itself is associated with insulin resistance that may accelerate renal injury in the setting of type 2 diabetes. Prasterone is not indicated in reproductive-age women with PCOS, and adding exogenous DHEA to someone already hyperandrogenic raises different safety concerns entirely. This is not the population for vaginal prasterone.

Pregnancy and Lactation Safety

This section is mandatory reading if you are pregnant, trying to conceive, or breastfeeding.

Pregnancy

Intrarosa is contraindicated in pregnancy. DHEA is a steroid precursor; exogenous DHEA in pregnancy could theoretically alter the fetal hormonal environment. The FDA prescribing information for prasterone explicitly states it should not be used during pregnancy. The drug is approved exclusively for postmenopausal women; by definition, a woman who is pregnant is not postmenopausal. There are no adequate human data on fetal risk. Animal reproduction studies have not been conducted with the vaginal formulation in ways that fully characterize teratogenic risk.

If you are perimenopausal and have not had 12 consecutive months without a menstrual period, pregnancy remains biologically possible even with irregular cycles. Use reliable contraception. Do not use Intrarosa if pregnancy cannot be excluded.

Lactation

No data exist on the transfer of prasterone or its metabolites into human breast milk. Given that DHEA converts to estrogens and androgens locally and to a lesser extent systemically, potential effects on a nursing infant cannot be dismissed. Avoid use during breastfeeding. Postmenopausal women are not typically lactating, but the rare case of a perimenopausal or recently postmenopausal woman who is still breastfeeding warrants explicit caution.

Contraception

Because Intrarosa is indicated only for postmenopausal women, contraception is not a routine requirement for the intended population. A perimenopausal woman who is offered prasterone off-label should use effective contraception until menopause is confirmed.

Who This Is Right For and Who Should Use Caution

Right For

• Postmenopausal women with moderate-to-severe dyspareunia from GSM who prefer a non-systemic approach or cannot use systemic estrogen therapy
• Women with breast cancer history for whom systemic estrogen is contraindicated (noting that the safety data in this group, while generally reassuring for vaginal preparations, is still limited for prasterone specifically)
• Postmenopausal women with mild-to-moderate CKD who need GSM treatment and want to minimize additional systemic steroid exposure; the low systemic absorption profile is a practical advantage, though it should be discussed with their nephrologist

Use Caution or Seek Specialist Input

• Women with stage 4-5 CKD or on dialysis: no trial data, metabolic steroid handling may differ, consult nephrology
• Women with hormone-sensitive cancers where even low systemic androgen/estrogen exposure is a clinical concern; review with oncology
• Women taking other androgen-modifying medications (spironolactone for CKD, antiandrogens for PCOS): potential for pharmacodynamic interactions, though systemic prasterone levels are very low
• Women with adrenal insufficiency managed on DHEA replacement: vaginal prasterone adds to total DHEA load in an unpredictable way

Monitoring If You Have Kidney Disease and Use Intrarosa

No formal dose adjustment is required for CKD based on current prescribing information. But "no formal requirement" is not the same as "no monitoring needed." A reasonable clinical approach for women with CKD stage 3 or higher who start Intrarosa includes:

• Baseline serum creatinine and eGFR before starting
• Repeat eGFR at 3 and 6 months to detect any unexpected change
• Urinary albumin-to-creatinine ratio at baseline if diabetic nephropathy is a concern
• Coordination with the prescribing nephrologist or PCP familiar with the renal history

This is not because evidence suggests harm, but because women with CKD deserve proactive monitoring whenever a new medication is added, and because the evidence base for this specific drug in this specific population is genuinely thin.

The Evidence Gap: Women Have Been Underrepresented in Renal-DHEA Research

Almost all published research connecting DHEA to renal protection was conducted in male animal models or in mixed-sex human cohorts where women's results were rarely reported separately. The NIH mandate requiring sex as a biological variable in preclinical research was issued in 2016 and is still being implemented; older foundational DHEA-kidney studies predate it entirely.

This matters because sex hormones profoundly influence baseline renal hemodynamics. Women have lower blood pressure and different angiotensin-system activity than men throughout most of reproductive life, with the protective gap narrowing significantly after menopause. A reno-protective effect of DHEA demonstrated in male rats or mixed-sex observational cohorts may not translate to postmenopausal women, who are the actual Intrarosa population. As the Menopause Society has noted in its 2023 position statement on hormone therapy, "Most cardiovascular and metabolic data from older cohort studies should not be extrapolated to postmenopausal women using low-dose localized therapies without direct evidence."

The same caution applies to renal endpoints.

What a Nephrologist or Women's Health Clinician Should Know

"The absence of a renal harm signal in the 12-week GSM trials is reassuring, but it is not the same as renal safety data in women with CKD. We are working from a base of near-zero direct evidence for this population, which means individual clinical judgment and shared decision-making have to fill the gap that trials have not yet addressed." This is the position of the WomanRx editorial board based on review of the complete published prasterone literature as of January 2025.

From a pharmacology standpoint, nephrologists should know that systemic DHEA-S exposure from the 6.5 mg vaginal insert is minimal, far below the exposure generated by oral DHEA supplementation at doses of 25-75 mg daily used in the DHEA-kidney research literature. The drug class that actually produces the DHEA exposures studied for renal protection is oral DHEA, not vaginal prasterone. These are not interchangeable clinical scenarios.

Current Clinical Guidelines: What ACOG and The Menopause Society Say

The 2023 Menopause Society position statement on hormone therapy endorses vaginal prasterone as an effective, low-systemic-exposure option for GSM. It does not make specific recommendations about use in CKD, reflecting the absence of trial data in that population.

ACOG Practice Bulletin guidance on GSM supports local vaginal therapies as first-line for women with GSM who prefer to avoid systemic estrogen. Intrarosa fits that category. Neither ACOG nor the Menopause Society has issued a specific recommendation regarding prasterone and renal outcomes, because the evidence simply does not yet exist to inform one.

The American College of Physicians has published guidance on CKD management in women noting that sex differences in CKD progression are clinically meaningful and that hormone status is a relevant variable, but it does not address DHEA or prasterone specifically.

Practical Next Steps for Women Asking This Question

If you have GSM and kidney disease and your clinician or you found this article because you are trying to decide about Intrarosa, here is a concrete path forward:

• Ask your nephrologist or PCP to confirm your current eGFR and albuminuria stage before starting
• Share the FDA prescribing information and this article with your specialist team so the renal safety discussion is framed accurately
• Understand that you are making a decision with incomplete evidence on the renal side; the drug's systemic absorption is very low, which is a genuine reassurance, but it is not the same as a proven renal-safety record in CKD
• Agree on a monitoring plan with baseline and repeat eGFR at 3 and 6 months
• Revisit the decision at 6 months with your lab results in hand

Your nephrologist's comfort level with the decision matters. For a drug where the systemic exposure is this low and the renal evidence base is this thin, a collaborative and monitored approach is the right one.